Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Multiple myeloma: current therapeutic approaches].

X Troussard1, F Bauduer, M Leporrier

  • 1Service d'hématologie clinique, CHRU Clemenceau, Caen, France.

Bulletin Du Cancer
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Conditional survival of children, adolescents and young adults (0-24 years) diagnosed with leukaemia during 2000-2014 world-wide: (CONCORD-3).

European journal of cancer (Oxford, England : 1990)·2025
Same author

Survival of European children, adolescents and young adults diagnosed with haematological malignancies in the period 2000-2013: Results from EUROCARE-6, a population-based study.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAF<sup>V600</sup>-mutated melanoma.

ESMO open·2023
Same author

Role of social status and social environment on net survival in patients with chronic lymphocytic leukemia: A high-resolution population-based study.

Cancer epidemiology·2022
Same author

[Treatment of iron deficiency anemia during pregnancy with oral iron: State of practice among midwives].

Gynecologie, obstetrique, fertilite & senologie·2021
Same author

Transfusional iron overload in patients with myelodysplastic syndromes: A 10-year retrospective survey from a French general hospital.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2020

Treatment for multiple myeloma varies by patient age and tumor burden. Early-stage disease requires no treatment, while established regimens like Melphalan Prednisone are standard for induction therapy.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Context:

  • Multiple myeloma treatment strategies are tailored based on patient age and tumor mass.
  • Stage I multiple myeloma typically does not require intervention.
  • Established therapeutic protocols guide treatment decisions.

Purpose:

  • To outline current therapeutic strategies for multiple myeloma.
  • To discuss the efficacy of various treatment modalities.
  • To highlight emerging therapies and supportive care.

Summary:

  • Melphalan Prednisone is a reference induction therapy, often preferred over polychemotherapies.
  • Interferon alpha shows promise during the steady-state phase.
  • VAD chemotherapy and body hemi-irradiation are effective, offering pain relief and tumor reduction.

Related Experiment Videos

  • High-dose chemotherapy with bone marrow transplantation is an option for younger patients.
  • Verapamil and anti-IL6 antibodies are under investigation.
  • Symptomatic management is crucial for this incurable condition.

    • Impact:

    • Provides a comprehensive overview of multiple myeloma management.
    • Informs clinical decision-making for oncologists and hematologists.
    • Highlights the importance of personalized treatment approaches and supportive care.